Special Issue "Recent Progress of Nanomedicine and Targeted Drug Delivery for Cancer Treatment 2.0"
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: 25 April 2024 | Viewed by 1447
Special Issue Editors
Interests: nanomedicine; biomaterials; drug/gene delivery; cancer immunotherapy; wound healing
Special Issues, Collections and Topics in MDPI journals
Interests: nanomaterials; nanomedicine; biomaterials; drug delivery; biomimetic; nanotechnology
Special Issue Information
Dear Colleagues,
Currently, cancer is the second leading cause of death worldwide and is the most complex and challenging disease known to mankind. Effective cancer treatment is still a great challenge due to the complex underlying mechanisms of tumorigenesis and tumor metastasis, as well as the intrinsic limitations of conventional cancer therapies. There is an urgent need for the discovery of novel therapeutic strategies with superior anticancer capabilities. In recent years, nano-drug delivery systems have been extensively investigated and applied as alternatives to conventional cancer treatments. Cancer nanomedicines aim at the targeted delivery of chemotherapeutic drugs to the tumor site, and utilize strategies such as passive targeting, active targeting and stimuli-triggered drug release, while simultaneously decreasing drug accumulation in normal tissues; together, they lead to an improved therapeutic efficacy and reduced side effects. Currently, several cancer nanomedicines are in regular use, and several others are in various stages of development.
This Special Issue will highlight recent progress in the development of novel nanomedicines and targeted drug delivery systems for cancer therapy. In this regard, we would like to invite authors to contribute original papers or comprehensive reviews on the development and possible applications of nanomedicines for cancer therapy.
Dr. Huijie Zhang
Dr. Shini Feng
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapy
- drug delivery
- targeted delivery
- nanocarriers
- nanoparticles
- controlled release
- tumor targeting
